88 results on '"Oka, S"'
Search Results
2. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice.
- Author
-
Liu W, Nakamura H, Shioji K, Tanito M, Oka S, Ahsan MK, Son A, Ishii Y, Kishimoto C, and Yodoi J
- Published
- 2004
3. Maternal serum triglyceride at 24--32 weeks' gestation and newborn weight in nondiabetic women with positive diabetic screens.
- Author
-
Kitajima, M, Oka, S, Yasuhi, I, Fukuda, M, Rii, Y, and Ishimaru, T
- Published
- 2001
4. Thoracic myelopathy caused by two-level herniated thoracic discs in a patient with leprotic neuropathy. A case report.
- Author
-
Iwasaki, Motoki, Okada, Kozo, Oka, Shiro, Iwasaki, M, Okada, K, and Oka, S
- Published
- 1993
5. Os odontoideum with posterior atlantoaxial instability.
- Author
-
Shirasaki, Nobuki, Okada, Kozo, Oka, Shiro, Hosono, Noboru, Yonenobu, Kazuo, Ono, Keiro, Shirasaki, N, Okada, K, Oka, S, Hosono, N, Yonenobu, K, and Ono, K
- Published
- 1991
6. Thoracic myelopathy caused by ossification of the ligamentum flavum. Clinicopathologic study and surgical treatment.
- Author
-
Okada, Kozo, Oka, Shiro, Kenjitohge, Ono, Keiro, Yonenobu, Kazuo, Hosoya, Tohru, Okada, K, Oka, S, Tohge, K, Ono, K, Yonenobu, K, and Hosoya, T
- Published
- 1991
7. Effect of maternal meal ingestion on fetal renal artery resistance.
- Author
-
Yasuhi, Ichiro, Hirai, Masanao, Oka, Satoshi, Nakajima, Hisayoshi, Ishimaru, Tadayuki, Yasuhi, I, Hirai, M, Oka, S, Nakajima, H, and Ishimaru, T
- Published
- 1997
- Full Text
- View/download PDF
8. Medial medullary infarction: a role of diffusion-weighted magnetic resonance imaging for stroke rehabilitation.
- Author
-
Maeshima S, Ueno M, Boh-oka S, and Ueyoshi A
- Published
- 2002
9. Characteristics of esophageal squamous cell carcinomas and lugol-voiding lesions in patients with head and neck squamous cell carcinoma.
- Author
-
Fukuhara T, Hiyama T, Tanaka S, Oka S, Yoshihara M, Arihiro K, and Chayama K
- Published
- 2010
- Full Text
- View/download PDF
10. Pupil dilation response to noxious stimulation during midazolam sedation.
- Author
-
Oka, S., Kim, B., Mikami, K., and Oi, Y.
- Published
- 2005
11. How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-risk T1 Colorectal Cancer?
- Author
-
Ouchi A, Komori K, Masahiro T, Toriyama K, Kajiwara Y, Oka S, Fukunaga Y, Hotta K, Ikematsu H, Tsukamoto S, Nagata S, Yamada K, Konno M, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Nakai K, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, and Ueno H
- Subjects
- Humans, Prognosis, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local pathology, Retrospective Studies, Treatment Outcome, Neoplasm Staging, Colorectal Neoplasms surgery, Colorectal Neoplasms pathology, Colonic Neoplasms pathology
- Abstract
Objective: To investigate how omitting additional surgery after local excision (LE) affects patient outcomes in high-risk T1 colorectal cancer (CRC)., Background: It is debatable whether additional surgery should be performed for all patients with high-risk T1 CRC regardless of the tolerability of invasive procedures., Methods: Patients who had received LE for T1 CRC at the Japanese Society for Cancer of the Colon and Rectum institutions between 2009 and 2016 were analyzed. Those who had received additional surgical resection and those who did not were matched one-on-one by the propensity score-matching method. A total of 401 propensity score-matched pairs were extracted from 1975 patients at 27 Japanese Society for Cancer of the Colon and Rectum institutions and were compared., Results: Regional lymph node metastasis was observed in 31 (7.7%) patients in the LE + surgery group. Comparatively, the incidence of oncologic adverse events was low in the LE-alone group, such as the 5-year cumulative risk of local recurrence (4.1%) or overall recurrence (5.5%). In addition, the difference in the 5-year cancer-specific survival between the LE + surgery and LE-alone groups was only 1.8% (99.7% and 97.9%, respectively), whereas the 5-year overall survival was significantly lower in the LE-alone group than in the LE + surgery group [88.5% vs 94.5%, respectively ( P = 0.002)]., Conclusions: Those who had decided to omit additional surgery at the dedicated center for CRC treatment presented a small number of oncologic events and a satisfactory cancer-specific survival, which may suggest an important role of risk assessment regarding nononcologic adverse events to achieve a best practice for each individual with high-risk T1 tumors., Competing Interests: The authors report no conflicts of interest., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Correction of HIV-Associated Facial Lipoatrophy: Autologous Fat Grafting versus Hyaluronic Acid Fillers.
- Author
-
Mashiko T, Tsukada K, Shirado T, Oka S, and Yoshimura K
- Published
- 2024
- Full Text
- View/download PDF
13. Speech Perception in Noise and Sound Localization for Cochlear Implant With Single-Sided Deafness Compared With Contralateral Routing of Signal Hearing Aids.
- Author
-
Oyamada S, Takahashi M, Furutate S, Oka S, Kubota E, Sakurai A, Uekusa T, Watanabe K, and Iwasaki S
- Subjects
- Adult, Humans, Prospective Studies, Treatment Outcome, Hearing Aids, Cochlear Implants, Cochlear Implantation, Sound Localization, Speech Perception, Hearing Loss, Deafness surgery, Deafness rehabilitation, Hearing Loss, Unilateral surgery
- Abstract
Objective: Cochlear implantation (CI) for the treatment of single-sided deafness (SSD) is a relatively new treatment modality. Although comparing the effectiveness of CI and contralateral routing of signal (CROS) hearing aids (HAs) is important, very few reports on this topic exist. In this study, objective assessments and subjective assessments were conducted to determine which SSD individuals would prefer CI or CROS HAs., Materials and Methods: Objective assessments (speech perception and sound localization) and subjective assessments (Hearing Handicap Inventory for Adults (HHIA), Abbreviated Profile of Hearing Aid Benefit (APHAB), MOS Short-Form 36-Item Health Survey version 2 (SF-36v2)) were performed on 87 SSD patients. Of the 87 SSD patients, 33 patients hoped for CROS HAs, and 17 patients hoped for CI. The CI group underwent subjective and objective assessments at 6 and 12 months postoperatively. The CROS HAs group underwent objective assessments at 1 month after wearing CROS HAs., Results: After the intervention, the localization ability was significantly improved in the CI group (p < 0.05) with no significant improvement in that of the CROS HAs group (p = 0.48). No significant improvement in speech perception in noise was observed in the CROS (Signal-to-Noise ratio + 10, p = 0.08; SN + 0, p = 0.17); however, a significant improvement in the CI group was observed at 12 months postoperatively. The APHAB subscale "background noise" and SF-36v2 health concepts of role-physical, general health, vitality, role-emotional, and mental health were significantly higher in the CI group., Conclusion: CI was superior to CROS HAs in speech perception in terms of noise and sound localization. Patients with postlingual acute-onset hearing loss and more handicaps and a more positive view of their hearing loss possibly tend to choose CI., Competing Interests: The authors disclose no financial relationships or conflict of interest., (Copyright © 2023, Otology & Neurotology, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
14. Electrocautery ablation therapy for anal intraepithelial carcinoma: A study protocol.
- Author
-
Ando N, Mizushima D, Takano M, Kitamura H, Shiojiri D, Nakamoto T, Aoki T, Watanabe K, Uemura H, Gatanaga H, and Oka S
- Subjects
- Humans, Pilot Projects, Neoplasm Recurrence, Local complications, Electrocoagulation, HIV Infections complications, Carcinoma in Situ pathology, Anus Neoplasms diagnosis
- Abstract
Background: Anal cancer is a human papillomavirus-related cancer. Screening with high-resolution anoscopy (HRA) and subsequent therapeutic intervention are increasingly recognized as the standard procedure for anal cancer. Generally, lesions suspected as being high-grade squamous intraepithelial lesions are biopsied and treated if they are grade 2 or 3 anal intraepithelial neoplasia (AIN). According to several studies, electrocautery ablation for grade 2 or 3 AIN is highly effective. However, relapse within and outside the targeted areas after the intervention is a clinical problem. In Japan, electrocautery ablation is not available at most facilities. Therefore, this study aims to investigate the efficacy and safety of electrocautery ablation., Methods: This single-arm, open-label, pilot intervention study will investigate the efficacy and safety of electrocautery ablative therapy using high-frequency medical devices. Patients diagnosed with grade 2 or 3 AIN will be included and will receive ablation treatment. Then, they will be followed up at 3 and 6 months after the procedure for HRA-guided sextant biopsy. To reduce the possibility of missed lesions before and after the intervention, we will perform HRA-guided sextant biopsy routinely. In this study, a sextant biopsy is defined as at least 6 biopsies in all directions, regardless of abnormal findings under HRA. The primary outcome is the recurrence rate at 6 months, and the secondary outcomes are the adverse event and recurrence rates at 3 months., Conclusion: This pilot study will provide data on the effectiveness and safety of electrocautery ablation as a treatment for grade 2 or 3 AIN., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
15. Safety and efficacy of capsule endoscopy for patients with newly diagnosed Crohn's disease: A multicenter retrospective study.
- Author
-
Kawano S, Oka S, Shiotani A, Hashimoto S, Takahashi S, Handa O, Takami T, Inaba T, Okada H, and Tanaka S
- Subjects
- Humans, Retrospective Studies, Intestine, Small pathology, Intestinal Mucosa pathology, Crohn Disease diagnosis, Crohn Disease pathology, Capsule Endoscopy adverse effects, Capsule Endoscopy methods
- Abstract
Crohn's disease (CD) is a chronic inflammatory disease that develops at a young age and frequently leads to intestinal resection. Capsule endoscopy (CE) can directly and non-invasively inspect the entire small bowel mucosa. We suspected that CE could be a good diagnostic tool for detecting CD in young patients. The aim of this study was to investigate the safety and efficacy of CE in patients with newly diagnosed CD and to evaluate the CE findings, especially in the upper small bowel of young patients. We retrospectively investigated 32 patients with newly diagnosed CD from 5 institutions. Patient characteristics, clinical course, and characteristics of CE findings were analyzed. The total small intestine observation rate was 93%, and the retention rate was 3% (1/32). No abnormality was identified by ileocolonoscopy in 46% (15/32), and transition of small bowel lesions (TSL) was found in 35% (12/34) of the patients. The frequency of longitudinal ulcers and cobblestones in the upper small intestine was significantly higher in younger patients (≤20 years). Moreover, positive findings in the upper small intestine were predominantly observed in younger patients (≤20 years). CE for patients with newly diagnosed CD was safe and useful, especially for the detection of upper small bowel lesions in young patients., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
16. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
- Author
-
Oka S, Ono K, and Nohgawa M
- Subjects
- Aged, Female, Humans, Leukemia-Lymphoma, Adult T-Cell pathology, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Prognosis, Antineoplastic Agents, Immunological therapeutic use, Brentuximab Vedotin therapeutic use, Drug Resistance, Neoplasm drug effects, Leukemia-Lymphoma, Adult T-Cell drug therapy, Salvage Therapy
- Abstract
Although treatments for adult T-cell leukemia/lymphoma in the past two decades have advanced, the current standard treatment for aggressive adult T-cell leukemia/lymphoma, particularly in patients who are not eligible for stem cell transplantation, remains inadequate; therefore, treatments to prolong the duration of remission and provide relevant benefits in terms of survival and quality of life are needed. Adult T-cell leukemia/lymphoma tumor cells express CD30 in some cases and the increased expression of CD30 is considered to be one of the causes of constitutive NF-κB activation in adult T-cell leukemia/lymphoma cells. Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas. Elderly patients treated with chemotherapy generally have higher rates of grade 3 or 4 adverse events; however a retrospective analysis demonstrated the safety and efficacy of brentuximab vedotin in adults ≥60 years with relapsed and refractory CD30-positive lymphomas. We herein report the clinical effects of brentuximab vedotin and the significance of CD30 expression in an elderly refractory/relapse adult T-cell leukemia/lymphoma patient. CD30 expression is associated with disease progression in adult T-cell leukemia/lymphoma patients and brentuximab vedotin may be a new and promising treatment option for these patients. Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed.
- Published
- 2020
- Full Text
- View/download PDF
17. Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan.
- Author
-
Nishijima T, Inaba Y, Kawasaki Y, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, and Oka S
- Subjects
- Adolescent, Adult, Cause of Death, Cohort Studies, Humans, Japan epidemiology, Male, Middle Aged, Prospective Studies, Sex Factors, Survival Analysis, Young Adult, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy, HIV Infections mortality
- Abstract
Objectives: To determine the mortality and causes of death in people living with HIV (PLHIV) in Japan., Design: A prospective cohort study at AIDS Clinical Center, Tokyo, which treats approximately 10% of PLHIV in care in Japan., Methods: Either PLHIV who visited our center for the first time between January 2005 and December 2014 or PLHIV who started their regular visit before January 2005 and visited us between January and March 2005 were included and followed by the end of 2016. Causes of death were defined according to the CoDe protocol., Results: Two thousand, seven hundred and ninety-seven PLHIV were analysed with total of 18 858 person-years of follow-up, which constitutes 14% of the estimated number of PLHIV in care in Japan. One hundred and sixty-five (5.9%) PLHIV died with all-cause mortality rate of 8.75 per 1000 person-years. All-cause mortality rate for PLHIV in care in Japan was estimated to be 8.75 per 1000 person-years (95% CI 5.53-12.0). Among causes of death, AIDS-defining illnesses accounted for 39% and malignancy contributed to 47%. Standardized mortality ratio (SMR) for all-cause mortality, malignancy-related mortality, and suicide were 5.96 (95% CI 5.05-6.87), 7.76 (95% CI 6.02-9.51), and 3.24 (95% CI 1.54-4.94), respectively. Even among the patients who were diagnosed early or without history of AIDS, SMR was four times higher than the general population., Conclusion: Mortality of PLHIV, even among those with early diagnosis, is substantially higher than that of the general population in Japan, highlighting the importance of further efforts towards prevention, early diagnosis and prompt treatment initiation.
- Published
- 2020
- Full Text
- View/download PDF
18. Association of HLA-DRB1 genotype with younger age onset and elder age onset rheumatoid arthritis in Japanese populations.
- Author
-
Oka S, Furukawa H, Shimada K, Hashimoto A, Komiya A, Tsunoda S, Saisho K, Tsuchiya N, Katayama M, Shinohara S, Matsui T, Fukui N, Sano H, Migita K, and Tohma S
- Subjects
- Adult, Aged, Alleles, Correlation of Data, Female, Gene Frequency, Genetic Predisposition to Disease, Humans, Immunologic Tests methods, Japan epidemiology, Male, Middle Aged, Age of Onset, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid epidemiology, Arthritis, Rheumatoid genetics, HLA-DRB1 Chains genetics
- Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by joint destructions and human leukocyte antigen (HLA)-DRB1 is an important genetic risk factor for RA and influences the phenotype of RA. The clinical features of elder age onset RA (EORA) were known to be different from those of younger age onset RA (YORA). Previous studies reported the different association pattern of DRB1 alleles with YORA or EORA. The associations of DRB1 genotype with these RA subsets remained almost unknown. We investigated the genotype association of DRB1 with YORA or EORA in Japanese populations.HLA genotyping was performed in Japanese RA patients and the association of allele or genotype carrier frequencies were analyzed.The genotype frequency of DRB104:05/DRB104:06 (P = .0204, OR 7.69, 95%CI 1.39-42.72), DRB104:05/DRB112:01 (P = .0050, OR 5.53, 95%CI 1.71-17.88), and DRB104:05/DRB115:01 (P = .0124, OR 3.34, 95%CI 1.39-8.02) in YORA was higher than EORA. However, the frequencies of DRB101:01/DRB104:05 in YORA was tended to be lower than EORA (P = .0784, OR 0.14, 95%CI 0.01-2.42). The gene dosage effect of the shared epitope alleles was detected in EORA, but not in YORA. Trans-complementing DQ heterodimer molecules, formed by DQA1 and DQB1 of the haplotypes with and without shared epitope alleles, might explain the higher genotype frequencies of "shared epitope /not shared epitope". Linear regression analyses showed the primary role of DQB104:01 allele for the age at onset of RA.This is the first report for the associations of DRB1 genotype with YORA or EORA in the Japanese population and the differential distribution of the genotypes was noted between these RA subsets. The involvement of DQ molecules for the age at onset of RA was suggested.
- Published
- 2019
- Full Text
- View/download PDF
19. Delayed Onset of Azacitidine-Associated Pneumotitis: A Case Report.
- Author
-
Oka S, Ono K, and Nohgawa M
- Subjects
- Aged, Female, Glucocorticoids therapeutic use, Humans, Lung diagnostic imaging, Lung drug effects, Myelodysplastic Syndromes drug therapy, Pneumonia diagnosis, Pneumonia drug therapy, Tomography, X-Ray Computed, Treatment Outcome, Antimetabolites, Antineoplastic adverse effects, Azacitidine adverse effects, Pneumonia chemically induced
- Published
- 2019
- Full Text
- View/download PDF
20. Successful treatment for Kaposi sarcoma inflammatory cytokine syndrome in a severe CD4+ lymphocytopenic HIV patient.
- Author
-
Suzuki T, Uemura H, Yanagawa Y, Mizushima D, Aoki T, Watanabe K, Tanuma J, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adult, Anti-Retroviral Agents therapeutic use, Antineoplastic Agents, Immunological therapeutic use, CD4 Lymphocyte Count, Humans, Male, Treatment Outcome, HIV Infections diagnosis, HIV Infections drug therapy, Sarcoma, Kaposi diagnosis, Sarcoma, Kaposi drug therapy
- Published
- 2019
- Full Text
- View/download PDF
21. Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study.
- Author
-
Sugiyama K, Kogure Y, Torii A, Shiraishi K, Yamada A, Ishida A, Shigematsu F, Nozawa K, Niwa H, Oka S, Nakahata M, Kitagawa C, Oki M, and Saka H
- Subjects
- Aged, Aged, 80 and over, Albumins administration & dosage, Albumins adverse effects, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic adverse effects, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms mortality, Male, Middle Aged, Paclitaxel administration & dosage, Paclitaxel adverse effects, Retrospective Studies, Salvage Therapy, Small Cell Lung Carcinoma mortality, Albumins therapeutic use, Antineoplastic Agents, Phytogenic therapeutic use, Lung Neoplasms drug therapy, Paclitaxel therapeutic use, Small Cell Lung Carcinoma drug therapy
- Abstract
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients.A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety.Thirty-one patients (median age, 69 [range, 56-80] years) were analyzed. The median follow-up period was 122 (range, 28-1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal.PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.
- Published
- 2019
- Full Text
- View/download PDF
22. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.
- Author
-
Nishijima T, Mutoh Y, Kawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, and Oka S
- Subjects
- Adult, Cross-Sectional Studies, Female, Humans, Kidney Function Tests, Male, Middle Aged, Prospective Studies, Tenofovir administration & dosage, HIV Infections complications, HIV Infections drug therapy, Kidney Diseases chemically induced, Kidney Diseases epidemiology, Kidney Tubules drug effects, Kidney Tubules pathology, Tenofovir adverse effects
- Abstract
Objective: Tenofovir disoproxil fumarate (TDF) increases the risk of kidney tubular dysfunction (KTD). This study was conducted to elucidate whether KTD persists after discontinuation of TDF., Design: A prospective cross-sectional study which enrolled 941 HIV-1-infected patients., Methods: KTD was predefined as the presence of at least two abnormalities among the five tubular markers (fractional excretion of phosphate, fractional excretion of uric acid, β2 microglobulinuria, N-acetyl-β-D-glucosaminidase, nondiabetic glycosuria). Logistic regression model was used to examine the association between KTD and cumulative TDF use, as well as current status of TDF use., Results: In total, 94% of study patients were men (median age 45, estimated glomerular filtration rate 75 ml/min per 1.73 m, CD4 575 cells/μl. About 98% were on antiretroviral therapy. In total, 64% of the patients ever used TDF and 39% currently used TDF. Twenty-nine percent used TDF for more than 5 years. KTD was diagnosed in 116 (12%) patients. In multivariate model, more than 5 years of TDF exposure and current TDF use [odds ratio (OR) 4.2, 95% confidence interval (CI) 2.37-7.56], more than 5 years and past TDF use (OR 2.4, 95% CI 1.09-5.33), less than 5 years and current TDF (OR 2.4, 95% CI 1.24-4.85), and less than 5 years and past TDF (OR 2.4, 95% CI 1.22-4.64) were all significantly associated with KTD, with never TDF use as reference. The results were the same using 4 and 3 years of exposure as the cutoff. However, with 2 years exposure, both less than 2 years and current TDF (OR 2.3, 95% CI 0.84-6.20) and less than 2 years and past TDF (OR 1.9, 95% CI 0.73-4.93) were not associated with KTD, whereas both more than 2 years and current TDF and more than 2 years and past TDF were associated., Conclusion: The association between cumulative TDF use and KTD was strong and robust. The results of the study suggested that TDF-related KTD might persist after discontinuation of TDF if patients used TDF for more than 2 years.
- Published
- 2018
- Full Text
- View/download PDF
23. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants.
- Author
-
Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, and Gatanaga H
- Subjects
- ATP Binding Cassette Transporter, Subfamily B blood, ATP Binding Cassette Transporter, Subfamily B genetics, ATP Binding Cassette Transporter, Subfamily G, Member 2 blood, Adult, Female, Genotype, HIV Infections blood, HIV Infections genetics, HIV Infections virology, HIV-1 drug effects, HIV-1 pathogenicity, Heterocyclic Compounds, 3-Ring administration & dosage, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear virology, Male, Middle Aged, Neoplasm Proteins blood, Oxazines, Piperazines, Polymorphism, Single Nucleotide, Pyridones, ATP Binding Cassette Transporter, Subfamily G, Member 2 genetics, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring blood, Neoplasm Proteins genetics
- Abstract
The ATP-binding cassette transporters B1 (ABCB1) and G2 (ABCG2) are both expressed in the intestine and known as efflux transporters of drugs. Dolutegravir was identified recently as a substrate of both ABCB1 and ABCG2. This study aimed to determine the relations between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and plasma dolutegravir concentrations. Plasma samples were obtained from 42 HIV-1-infected patients treated with dolutegravir-containing regimens 0.5-4 h after dolutegravir dosing. Plasma dolutegravir concentrations were measured by liquid chromatography-mass spectrometry. Genomic DNA was isolated from peripheral blood mononuclear cells. Genotyping of allelic variants of ABCB1 1236 C>T (rs1128503), 2677 G>T/A (rs2032582), 3435 C>T (rs1045642), 4036 A>G (rs3842), and ABCG2 421 C>A (rs2231142) was performed using the TaqMan drug metabolism assays. None of the genotypes in ABCB1 1236 C>T, 2677 G>T/A, 3435 C>T, and 4036 A>G correlated with plasma dolutegravir concentration. In contrast, the mean peak plasma concentration of dolutegravir was significantly higher in the genotypes of ABCG2 421 AA (5002 ng/ml, n=3) compared with the genotypes of ABCG2 421 CC (2569 ng/ml, n=22) and ABCG2 421 CA (2479 ng/ml, n=17) (P=0.0005). The speculated peak level of plasma dolutegravir concentration was significantly higher in ABCG2 genetic variant holders, probably, at least in part, because of low expression levels of efflux transporters in the intestines associated with these genetic variants.
- Published
- 2017
- Full Text
- View/download PDF
24. Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection.
- Author
-
Gatanaga H, Brumme ZL, Adland E, Reyes-Terán G, Avila-Rios S, Mejía-Villatoro CR, Hayashida T, Chikata T, Van Tran G, Van Nguyen K, Meza RI, Palou EY, Valenzuela-Ponce H, Pascale JM, Porras-Cortés G, Manzanero M, Lee GQ, Martin JN, Carrington MN, John M, Mallal S, Poon AFY, Goulder P, Takiguchi M, and Oka S
- Subjects
- Global Health, HIV Infections virology, HIV Reverse Transcriptase genetics, HIV-1 enzymology, HIV-1 genetics, HLA-B18 Antigen genetics, Humans, Polymorphism, Genetic, Rilpivirine pharmacology, Anti-Retroviral Agents pharmacology, Drug Resistance, Viral, HIV Infections prevention & control, HIV-1 immunology, Immune Evasion, Mutation, Missense, Pre-Exposure Prophylaxis
- Abstract
Objective: Long-acting rilpivirine is a candidate for preexposure prophylaxis (PrEP) for prevention of HIV-1 infection. However, rilpivirine resistance mutations at reverse transcriptase codon 138 (E138X) occur naturally in a minority of HIV-1-infected persons; in particular those expressing human leukocyte antigen (HLA)-B18 where reverse transcriptase-E138X arises as an immune escape mutation. We investigate the global prevalence, B18-linkage and replicative cost of reverse transcriptase-E138X and its regional implications for rilpivirine PrEP., Methods: We analyzed linked reverse transcriptase-E138X/HLA data from 7772 antiretroviral-naive patients from 16 cohorts spanning five continents and five HIV-1 subtypes, alongside unlinked global reverse transcriptase-E138X and HLA frequencies from public databases. E138X-containing HIV-1 variants were assessed for in-vitro replication as a surrogate of mutation stability following transmission., Results: Reverse transcriptase-E138X variants, where the most common were rilpivirine resistance-associated mutations E138A/G/K, were significantly enriched in HLA-B18-positive individuals globally (P = 3.5 × 10) and in all HIV-1 subtypes except A. Reverse transcriptase-E138X and B18 frequencies correlated positively in 16 cohorts with linked HIV/HLA genotypes (Spearman's R = 0.75; P = 7.6 × 10) and in unlinked HIV/HLA data from 43 countries (Spearman's R = 0.34, P = 0.02). Notably, reverse transcriptase-E138X frequencies approached (or exceeded) 10% in key epidemic regions (e.g. sub-Saharan Africa, Southeastern Europe) where B18 is more common. This, along with the observation that reverse transcriptase-E138X variants do not confer in-vitro replicative costs, supports their persistence, and ongoing accumulation in circulation over time., Conclusions: Results illustrate the potential for a natural immune-driven HIV-1 polymorphism to compromise antiretroviral-based prevention, particularly in key epidemic regions. Regional reverse transcriptase-E138X surveillance should be undertaken before use of rilpivirine PrEP.
- Published
- 2017
- Full Text
- View/download PDF
25. Effects of vestibular rehabilitation on gait performance in poststroke patients: a pilot randomized controlled trial.
- Author
-
Mitsutake T, Sakamoto M, Ueta K, Oka S, and Horikawa E
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Gait Disorders, Neurologic psychology, Humans, Male, Middle Aged, Pilot Projects, Gait Disorders, Neurologic rehabilitation, Paresis rehabilitation, Physical Therapy Modalities, Reflex, Vestibulo-Ocular, Stroke Rehabilitation
- Abstract
The effects of vestibular rehabilitation on poststroke patients are unknown. This study aimed to investigate whether or not vestibular rehabilitation would improve both the vestibulo-ocular reflex and gait performance of patients with poststroke hemiparesis. Twenty-eight patients with stroke were assigned randomly to either an experimental group (N=14) or a control group (N=14). The experimental group performed the conventional physical therapy for 40 min and vestibular rehabilitation for 20 min, as a 60 min session, during the first 3 weeks and then completed only the conventional intervention for 60 min for the following 3 weeks. The control group performed only the 60 min conventional physical therapy for 6 weeks. Both groups were measured using the gaze stabilization test, the 10 m walking test, the timed up and go test, and the dynamic gait index. Patients were assessed at baseline, and at 3 and 6 weeks. Although the control group showed no significant difference in any outcome measures, the experimental group showed an improvement in gaze stabilization test scoring, which increased significantly after 3 weeks compared with the baseline (P=0.030). The dynamic gait index was also significantly increased after 3 and 6 weeks compared with the baseline (P=0.049 and 0.024, respectively). This study indicated that vestibular rehabilitation might improve poststroke patients' vestibulo-ocular reflex. Moreover, patients might show improved gait performance at least up to 3 weeks after the vestibular intervention by the sensory reweight to coordinate vestibular input.
- Published
- 2017
- Full Text
- View/download PDF
26. Poor gait performance is influenced with decreased vestibulo-ocular reflex in poststroke patients.
- Author
-
Mitsutake T, Sakamoto M, Ueta K, Oka S, and Horikawa E
- Subjects
- Accelerometry, Age Factors, Aged, Exercise Test, Female, Head, Hemiplegia etiology, Humans, Male, Motor Activity physiology, Regression Analysis, Stroke complications, Gait physiology, Hemiplegia physiopathology, Reflex, Vestibulo-Ocular physiology, Stroke physiopathology
- Abstract
The vestibulo-ocular reflex (VOR) exerts a significant influence on gait performance. Therefore, a decrease in VOR function could worsen gait impairments in patients with poststroke hemiparesis. The effects of decreased VOR function on gait performance could be further exacerbated by aging-related physical weakness and impaired motor function of the hemiparetic lower limb. The aim of our study was to evaluate the possible synergistic effect of aging and impairment in lower extremity function and the VOR on walking ability of poststroke hemiplegic patients. The VOR was evaluated, using the gaze-stabilization test (GST), in 75 patients with a poststroke hemiplegia. Lower extremity function was assessed using the Fugl-Meyer assessment (FMA-LE). Gait performance was evaluated using the 10-m walking test, the timed up-and-go, and the dynamic gait index (DGI). The relationships between gait performance and age, FMA-LE and GST, as well as whether age, FMA-LE, and/or GST were significant predictors of gait performance were evaluated. The 10-m walking test, timed up-and-go and DGI were significantly correlated to the FMA-LE and GST (P<0.05). On stepwise multiple regression analysis, the GST remained a significant predictor of the DGI (P<0.001). The present study indicates that decreased VOR function after stroke contributes to impairments in gait both in simple and in dual-task walking tests.
- Published
- 2017
- Full Text
- View/download PDF
27. Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy.
- Author
-
Ku NS, Jiamsakul A, Ng OT, Yunihastuti E, Cuong DD, Lee MP, Sim BLH, Phanuphak P, Wong WW, Kamarulzaman A, Zhang F, Pujari S, Chaiwarith R, Oka S, Mustafa M, Kumarasamy N, Van Nguyen K, Ditangco R, Kiertiburanakul S, Merati TP, Durier N, and Choi JY
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Drug Therapy, Combination, Female, HIV Infections blood, Humans, Lymphocyte Count, Male, Middle Aged, Treatment Failure, Viral Load drug effects, Anti-HIV Agents therapeutic use, CD8-Positive T-Lymphocytes drug effects, HIV Infections drug therapy
- Abstract
Elevated CD8 counts with combination antiretroviral therapy (cART) initiation may be an early warning indicator for future treatment failure. Thus, we investigated whether elevated CD8 counts were associated with virological failure (VF) in the first 4 years of cART in Asian HIV-infected patients in a multicenter regional cohort.We included patients from the TREAT Asia HIV Observational Database (TAHOD). Patients were included in the analysis if they started cART between 1996 and 2013 with at least one CD8 measurement within 6 months prior to cART initiation and at least one CD8 and viral load (VL) measurement beyond 6 months after starting cART. We defined VF as VL ≥400 copies/mL after 6 months on cART. Elevated CD8 was defined as CD8 ≥1200 cells/μL. Time to VF was modeled using Cox regression analysis, stratified by site.In total, 2475 patients from 19 sites were included in this analysis, of whom 665 (27%) experienced VF in the first 4 years of cART. The overall rate of VF was 12.95 per 100 person-years. In the multivariate model, the most recent elevated CD8 was significantly associated with a greater hazard of VF (HR = 1.35, 95% CI 1.14-1.61; P = 0.001). However, the sensitivity analysis showed that time-lagged CD8 measured at least 6 months prior to our virological endpoint was not statistically significant (P = 0.420).This study indicates that the relationship between the most recent CD8 count and VF was possibly due to the CD8 cells reacting to the increase in VL rather than causing the VL increase itself. However, CD8 levels may be a useful indicator for VF in HIV-infected patients after starting cART.
- Published
- 2016
- Full Text
- View/download PDF
28. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
- Author
-
Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, and Gatanaga H
- Subjects
- Adult, Antiviral Agents administration & dosage, Female, Humans, Longitudinal Studies, Male, Middle Aged, Renal Insufficiency pathology, Tenofovir administration & dosage, Antiviral Agents adverse effects, Biomarkers urine, HIV Infections complications, HIV Infections drug therapy, Renal Insufficiency diagnosis, Tenofovir adverse effects, beta 2-Microglobulin urine
- Abstract
Objective: In nephrotoxicity induced by tenofovir disoproxil fumarate (TDF), tubular dysfunction precedes the decline in GFR, suggesting that tubular markers are more sensitive than estimated glomerular filtration rate (eGFR). The hypothesis that urinary β2 microglobulin (β2 M), a tubular function marker, can predict TDF-renal dysfunction in HIV-1-infected patients was tested., Design: A single-center observational study., Methods: The inclusion criteria were: HIV-1-infected patients who started TDF-containing antiretroviral therapy from 2004 to 2013, urinary β2 M after and closest to the day of TDF initiation within 180 days (termed 'β2 M after TDF') was measured. The associations between 'β2 M after TDF' and four renal end points (>10 ml/min per 1.73 m decrement in eGFR relative to baseline, >20 decrement, >25% decrement, and eGFR < 60) were estimated with logistic regression model. The association between 'β2 M after TDF' and longitudinal changes in eGFR after initiation of TDF was estimated with a mixed-model., Results: A total 655 study patients were analyzed (96% men, median age 38, median CD4 238 cells/μl, 63% treatment naïve). The median baseline eGFR was 117 ml/min per 1.73 m (IQR 110-125), and the median duration of TDF use was 3.32 years (IQR 2.02-5.31). 'β2 M after TDF' was significantly associated with more than 20 decrement in eGFR (P = 0.024) and more than 25% decrement (P = 0.014), and was marginally associated with eGFR less than 60 (P = 0.076). It was also significantly associated with the longitudinal eGFR after initiation of TDF (P < 0.0001). 'β2 M after TDF' of 1700 μg/l was identified as the optimal cutoff value for the prediction of longitudinal eGFR., Conclusions: Urinary β2 M measured within 180 days after initiation of TDF predicts renal dysfunction related to long-term TDF use.
- Published
- 2016
- Full Text
- View/download PDF
29. A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection.
- Author
-
Van Tran G, Chikata T, Carlson JM, Murakoshi H, Nguyen DH, Tamura Y, Akahoshi T, Kuse N, Sakai K, Sakai S, Cobarrubias K, Oka S, Brumme ZL, Van Nguyen K, and Takiguchi M
- Subjects
- Adult, Asian People, CD4 Lymphocyte Count, Cross-Sectional Studies, Female, HIV Infections immunology, HIV-1 classification, HIV-1 isolation & purification, Humans, Male, Mutation, Plasma virology, Viral Load, nef Gene Products, Human Immunodeficiency Virus genetics, HIV Infections pathology, HIV Infections virology, HIV-1 genetics, HLA Antigens metabolism, Polymorphism, Genetic, gag Gene Products, Human Immunodeficiency Virus genetics, pol Gene Products, Human Immunodeficiency Virus genetics
- Abstract
Objectives: Identification of human leukocyte antigen-associated HIV-1 polymorphisms (HLA-APs) in different global populations furthers our understanding of HIV-1 pathogenesis and may help identify candidate immunogens for HIV vaccines targeted to these populations. Although numerous population-based studies identifying HLA-APs have been conducted in HIV-1 subtype B- and subtype C-infected cohorts, few have focused on subtype A/E., Design: We investigated HLA-APs in a cohort of chronically HIV-1 subtype A/E-infected Vietnamese individuals., Methods: HLA-APs in HIV-1 Gag, Pol, and Nef regions from 388 treatment-naive individuals chronically infected with HIV-1 subtype A/E were analyzed using phylogenetically informed approaches., Results: A total of 303 HLA-APs were identified. HLA-APs occurring at six positions in Gag and six positions in Pol were significantly associated with higher plasma viral load (pVL), whereas HLA-APs occurring at two positions in Gag and 13 positions in Pol were significantly associated with lower CD4 T-cell counts. Furthermore, the proportion of Pol codons harboring an HLA-AP specific to the host's HLA correlated positively with HIV-1 pVL (R = 0.22; P < 0.0001) and inversely with CD4 T-cell counts (R = -0.32; P < 0.0001). Similarly, the proportion of HLA-associated Gag codons harboring host-specific HLA-AP correlated inversely with CD4 T-cell counts (R = -0.13; P = 0.01)., Conclusion: These significant associations between HIV-1 amino acids adapted to Vietnamese HLA alleles and higher pVL and lower CD4 T-cell counts suggests that accumulation of cytotoxic T cells escape mutations may influence clinical outcomes in HIV-1 subtype A/E-infected Vietnamese individuals.
- Published
- 2016
- Full Text
- View/download PDF
30. Greater Cervical Muscle Fat Infiltration Evaluated by Magnetic Resonance Imaging is Associated With Poor Postural Stability in Patients With Cervical Spondylotic Radiculopathy.
- Author
-
Mitsutake T, Sakamoto M, Chyuda Y, Oka S, Hirata H, Matsuo T, Oishi T, and Horikawa E
- Subjects
- Case-Control Studies, Cervical Vertebrae physiopathology, Cervical Vertebrae surgery, Cross-Sectional Studies, Humans, Magnetic Resonance Imaging, Paraspinal Muscles anatomy & histology, Radiculopathy epidemiology, Radiculopathy pathology, Spondylosis epidemiology, Spondylosis pathology, Adipose Tissue anatomy & histology, Neck anatomy & histology, Posture physiology, Radiculopathy physiopathology, Spondylosis physiopathology
- Abstract
Study Design: A population-based, cross-sectional study., Objective: The aim of this study was to quantitatively evaluate the relationship between static postural stability and fat infiltration within cervical multifidus muscle in patients with cervical spondylotic radiculopathy (CSR)., Summary of Background Data: CSR causes denervation by compression of nerve roots. This denervation is detected by fatty infiltration or results in fatty infiltration within muscles. Proprioceptive information in cervical multifidus muscle plays an important role in coordinated movement of postural stability; however, there have been few studies evaluating the relationship between postural stability and fat infiltration within cervical multifidus muscle among CSR patients., Methods: Sixteen CSR patients with C6 injuries and 25 age-matched healthy controls underwent magnetic resonance images to examine bilateral cervical multifidus muscle. For evaluation of fat within muscle, a muscle fat index (MFI) was calculated by using both measurement of cervical multifidus muscle and intermuscular fat. Participants' postural stability at upright position with eyes-opened and eyes-closed for 60 seconds was examined by a platform. Two parameters, the total length and the area of the center of pressure (COP), were used for evaluation., Results: The CSR group showed significantly poorer postural stability than the control group (eyes-opened the total length; P < 0.05, eyes-closed the total length; P < 0.05, eyes-closed the area; P < 0.05). There were significant group differences at C4, C5, and C6 MFI (P < 0.05). In the CSR group, a correlation analysis demonstrated that the age, C4, C5, and C6 MFI values were significantly associated with the eyes-closed the total length of the COP (P < 0.05)., Conclusions: Fat infiltration within muscle could lead to inhibition of normal activity of musculature. The present study suggests that fat within cervical multifidus muscle could directly cause postural instability in static standing, even though the proprioceptive information has normal lower limbs.
- Published
- 2016
- Full Text
- View/download PDF
31. Peroxisome Proliferator Activated Receptor-α Association With Silent Information Regulator 1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart.
- Author
-
Oka S, Zhai P, Yamamoto T, Ikeda Y, Byun J, Hsu CP, and Sadoshima J
- Subjects
- Animals, Case-Control Studies, Dimerization, Disease Models, Animal, Heart Failure genetics, Humans, Mice, PPAR alpha genetics, RNA, Messenger metabolism, Retinoid X Receptors genetics, Sirtuin 1 genetics, Fatty Acids metabolism, Heart Failure metabolism, Lipid Metabolism physiology, PPAR alpha metabolism, Retinoid X Receptors metabolism, Sirtuin 1 metabolism
- Abstract
Background: Heart failure is accompanied by changes in cardiac metabolism characterized by reduced fatty acid (FA) utilization. However, the underlying mechanism and its causative involvement in the progression of heart failure are poorly understood. The peroxisome proliferator activated receptor-α (PPARα)/retinoid X receptor (RXR) heterodimer promotes transcription of genes involved in FA metabolism through binding to the PPAR response element, called direct repeat 1 (DR1). Silent information regulator 1 (Sirt1) is a histone deacetylase, which interacts with PPARα., Methods and Results: To investigate the role of PPARα in the impaired FA utilization observed during heart failure, genetically altered mice were subjected to pressure overload. The DNA binding of PPARα, RXRα, and Sirt1 to DR1 was evaluated with oligonucleotide pull-down and chromatin immunoprecipitation assays. Although the binding of PPARα to DR1 was enhanced in response to pressure overload, that of RXRα was attenuated. Sirt1 competes with RXRα to dimerize with PPARα, thereby suppressing FA utilization in the failing heart. DR1 sequence analysis indicated that the typical DR1 sequence favors PPARα/RXRα heterodimerization, whereas the switch from RXRα to Sirt1 takes place on degenerate DR1s. Sirt1 bound to PPARα through a region homologous to the PPARα binding domain in RXRα. A short peptide corresponding to the RXRα domain not only inhibited the interaction between PPARα and Sirt1 but also improved FA metabolism and ameliorated cardiac dysfunction., Conclusions: A change in the heterodimeric partner of PPARα from RXRα to Sirt1 is responsible for the impaired FA metabolism and cardiac dysfunction in the failing heart., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
32. Upper Gastrointestinal Symptoms Predictive of Candida Esophagitis and Erosive Esophagitis in HIV and Non-HIV Patients: An Endoscopy-Based Cross-Sectional Study of 6011 Patients.
- Author
-
Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, Sekine K, Okubo H, Watanabe K, Sakurai T, Yokoi C, Mimori A, Oka S, Uemura N, and Akiyama J
- Subjects
- Adult, Candidiasis physiopathology, Cross-Sectional Studies, Esophagitis diagnosis, Esophagitis microbiology, Esophagoscopy, Female, HIV Infections physiopathology, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Candidiasis epidemiology, Esophagitis epidemiology, Esophagitis physiopathology, HIV Infections epidemiology
- Abstract
Upper gastrointestinal (GI) symptoms are common in both HIV and non-HIV-infected patients, but the difference of GI symptom severity between 2 groups remains unknown. Candida esophagitis and erosive esophagitis, 2 major types of esophagitis, are seen in both HIV and non-HIV-infected patients, but differences in GI symptoms that are predictive of esophagitis between 2 groups remain unknown. We aimed to determine whether GI symptoms differ between HIV-infected and non-HIV-infected patients, and identify specific symptoms of candida esophagitis and erosive esophagitis between 2 groups.We prospectively enrolled 6011 patients (HIV, 430; non-HIV, 5581) who underwent endoscopy and completed questionnaires. Nine upper GI symptoms (epigastric pain, heartburn, acid regurgitation, hunger cramps, nausea, early satiety, belching, dysphagia, and odynophagia) were evaluated using a 7-point Likert scale. Associations between esophagitis and symptoms were analyzed by the multivariate logistic regression model adjusted for age, sex, and proton pump inhibitors.Endoscopy revealed GI-organic diseases in 33.4% (2010/6.011) of patients. The prevalence of candida esophagitis and erosive esophagitis was 11.2% and 12.1% in HIV-infected patients, respectively, whereas it was 2.9% and 10.7 % in non-HIV-infected patients, respectively. After excluding GI-organic diseases, HIV-infected patients had significantly (P < 0.05) higher symptom scores for heartburn, hunger cramps, nausea, early satiety, belching, dysphagia, and odynophagia than non-HIV-infected patients. In HIV-infected patients, any symptom was not significantly associated with CD4 cell count. In multivariate analysis, none of the 9 GI symptoms were associated with candida esophagitis in HIV-infected patients, whereas dysphagia and odynophagia were independently (P < 0.05) associated with candida esophagitis in non-HIV-infected patients. However, heartburn and acid regurgitation were independently (P < 0.05) associated with erosive esophagitis in both patient groups. The internal consistency test using Cronbach's α revealed that the 9 symptom scores were reliable in both HIV (α, 0.86) and non-HIV-infected patients (α, 0.85).This large-scale endoscopy-based study showed that HIV-infected patients have greater GI symptom scores compared with non-HIV-infected patients even after excluding GI-organic diseases. None of the upper GI symptoms predict candida esophagitis in HIV-infected patients, but dysphagia and odynophagia predict candida esophagitis in non-HIV-infected patients. Heartburn and acid regurgitation predict erosive esophagitis in both patient groups., Competing Interests: The authors have no conflicts of interest to disclose.
- Published
- 2015
- Full Text
- View/download PDF
33. Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
- Author
-
Nishijima T, Kawasaki Y, Tanaka N, Gatanaga H, and Oka S
- Subjects
- Female, Humans, Male, Adenine analogs & derivatives, Anti-HIV Agents adverse effects, Body Weight, Glomerular Filtration Rate drug effects, HIV Infections drug therapy, Organophosphonates adverse effects, Renal Insufficiency chemically induced
- Published
- 2015
- Full Text
- View/download PDF
34. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
- Author
-
Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, and Oka S
- Subjects
- Adenine adverse effects, Adenine therapeutic use, Adult, Anti-HIV Agents therapeutic use, Cohort Studies, Female, HIV Infections complications, HIV Infections virology, HIV-1 isolation & purification, Humans, Longitudinal Studies, Male, Organophosphonates therapeutic use, Tenofovir, Tokyo, Adenine analogs & derivatives, Anti-HIV Agents adverse effects, Body Weight, Glomerular Filtration Rate drug effects, HIV Infections drug therapy, Organophosphonates adverse effects, Renal Insufficiency chemically induced
- Abstract
Objectives: To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity., Design: A single-center, observational study in Tokyo, Japan., Methods: We performed a 10 years cohort study of 792 HIV-1-infected patients. The effect of long-term TDF use on estimated glomerular filtration rate (eGFR) was investigated on treatment-naive patients who started TDF-containing antiretroviral therapy (n = 422) and those who started abacavir-containing antiretroviral therapy as control (n = 370). Three renal endpoints were examined by the logistic regression model: decrement in eGFR of higher than 10 ml/min per 1.73 m relative to the baseline, more than 25% decrement in eGFR, and eGFR lower than 60 ml/min per 1.73 m at least 3 months apart. The loss in eGFR was estimated using linear mixed models for repeated measures., Results: The median weight at baseline was 63 kg. TDF use increased the risk of all three renal outcomes compared with the control group: higher than 10 ml/min per 1.73 m decrement in eGFR [adjusted odds ratio (OR) = 2.1, 95% confidence interval (CI) 1.45-3.14, P < 0.001], more than 25% decrement (adjusted OR = 2.1, 95% CI 1.50-2.90, P < 0.001), and eGFR lower than 60 ml/min per 1.73 m at least 3 months apart (adjusted OR = 3.9, 95% CI 1.62-9.36, P = 0.002). The cumulative mean loss relative to the control after 1, 2, 3, 4, and 5 years of TDF exposure was -3.8, -3.6, -5.5, -6.6, and -10.3 ml/min per 1.73 m, respectively, indicating that the loss in eGFR increased over time (P < 0.001)., Conclusion: In this cohort of patients with low body weight, TDF exposure increased the risk of renal dysfunction. Furthermore, the loss in eGFR relative to the control increased continuously up to 5 years.
- Published
- 2014
- Full Text
- View/download PDF
35. DNA methylation profiling can classify HIV-associated lymphomas.
- Author
-
Matsunaga A, Hishima T, Tanaka N, Yamasaki M, Yoshida L, Mochizuki M, Tanuma J, Oka S, Ishizaka Y, Shimura M, and Hagiwara S
- Subjects
- Adult, Aged, Cohort Studies, Female, Humans, Lymphoma diagnosis, Male, Microarray Analysis methods, Middle Aged, Prognosis, DNA chemistry, DNA Methylation, HIV Infections complications, Lymphoma classification, Lymphoma pathology, Pathology, Molecular methods
- Abstract
Background: HIV-positive patients have a 60-fold to 200-fold increased incidence of non-Hodgkin lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, and primary central nervous system lymphoma. HIV-associated lymphomas frequently have features such as extranodal involvement, decreased responses to standard chemotherapy, and high relapse rates, which indicate a poor prognosis. General pathological features do not clearly differentiate HIV-associated lymphomas from non-HIV lymphomas., Methods: To investigate the features of HIV-associated lymphomas, we performed genome-wide DNA methylation profiling of HIV and non-HIV lymphomas using Illumina GoldenGate Methylation Cancer Panel I and Illumina Infinium HumanMethylation450 BeadChip microarrays. DNA methylation profiles in HIV-associated and non-HIV lymphomas were characterized using unsupervised hierarchical clustering analyses., Results: The analyses of promoter regions revealed unique DNA methylation profiles in HIV-associated lymphomas, suggesting profile differences compared with non-HIV lymphomas, which implies specific gene regulation in HIV-associated lymphoma involving DNA methylation. Based on HumanMethylation450 BeadChip data, 2541 target sites were selected as differing significantly in comparisons between HIV-associated and non-HIV-associated lymphomas using Wilcoxon's rank-sum test (P <0.05) and Δβ values more than 0.30. Recurrent cases of HIV-associated lymphoma had different profiles compared with nonrecurrent HIV lymphomas., Conclusion: DNA methylation profiling indicated that 2541 target sites differed significantly in HIV-associated lymphoma, which may partly explain the poor prognosis. Our data indicate that the methylation profiles of target genes have potential in elucidating HIV-associated lymphomagenesis and can serve as new prognostic markers.
- Published
- 2014
- Full Text
- View/download PDF
36. Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-1α and upregulation of peroxisome proliferator-activated receptor-α.
- Author
-
Matsushima S, Kuroda J, Ago T, Zhai P, Ikeda Y, Oka S, Fong GH, Tian R, and Sadoshima J
- Subjects
- Animals, Enzyme Activation physiology, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Male, Membrane Glycoproteins antagonists & inhibitors, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, NADPH Oxidase 2, NADPH Oxidase 4, NADPH Oxidases antagonists & inhibitors, PPAR alpha physiology, Reperfusion Injury enzymology, Reperfusion Injury physiopathology, Down-Regulation physiology, Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors, Membrane Glycoproteins deficiency, NADPH Oxidases deficiency, PPAR alpha biosynthesis, Reperfusion Injury metabolism, Up-Regulation physiology
- Abstract
Rationale: NADPH oxidase (Nox) 2 and Nox4 are major components of the Nox family which purposefully produce reactive oxidative species, namely O2(-) and H2O2, in the heart. The isoform-specific contribution of Nox2 and Nox4 to ischemia/reperfusion (I/R) injury is poorly understood., Objective: We investigated the role of Nox2 and Nox4 in mediating oxidative stress and myocardial injury during I/R using loss-of-function mouse models., Methods and Results: Systemic (s) Nox2 knockout (KO), sNox4 KO, and cardiac-specific (c) Nox4 KO mice were subjected to I/R (30 minutes/24 hours, respectively). Both myocardial infarct size/area at risk and O2(-) production were lower in sNox2 KO, sNox4 KO, and cNox4 KO than in wild-type mice. Unexpectedly, however, the myocardial infarct size/area at risk was greater, despite less O2(-) production, in sNox2 KO+cNox4 KO (double-KO) mice and transgenic mice (Tg) with cardiac-specific expression of dominant-negative Nox, which suppresses both Nox2 and Nox4, than in wild-type or single KO mice. Hypoxia-inducible factor-1α was downregulated whereas peroxisome proliferator-activated receptor-α was upregulated in Tg-dominant-negative Nox mice. A cross with mice deficient in prolyl hydroxylase 2, which hydroxylates hypoxia-inducible factor-1α, rescued the I/R injury and prevented upregulation of peroxisome proliferator-activated receptor-α in Tg-dominant-negative Nox mice. A cross with peroxisome proliferator-activated receptor-α KO mice also attenuated the injury in Tg- dominant-negative Nox mice., Conclusions: Both Nox2 and Nox4 contribute to the increase in reactive oxidative species and injury by I/R. However, low levels of reactive oxidative species produced by either Nox2 or Nox4 regulate hypoxia-inducible factor-1α and peroxisome proliferator-activated receptor-α, thereby protecting the heart against I/R, suggesting that Noxs also act as a physiological sensor for myocardial adaptation.
- Published
- 2013
- Full Text
- View/download PDF
37. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
- Author
-
Nishijima T, Komatsu H, Teruya K, Tanuma J, Tsukada K, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adenine adverse effects, Adenine analogs & derivatives, Adenine therapeutic use, Anti-HIV Agents adverse effects, Darunavir, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Dideoxynucleosides adverse effects, Dideoxynucleosides therapeutic use, Drug Combinations, Drug Therapy, Combination, Emtricitabine, HIV Infections blood, HIV Infections virology, HIV Protease Inhibitors adverse effects, Humans, Lamivudine adverse effects, Lamivudine therapeutic use, Organophosphonates adverse effects, Organophosphonates therapeutic use, Ritonavir adverse effects, Ritonavir therapeutic use, Sulfonamides adverse effects, Sulfonamides therapeutic use, Tenofovir, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1 immunology, Viral Load immunology
- Abstract
The efficacy and safety of fixed-dose abacavir/lamivudine against tenofovir/emtricitabine, both with once-daily darunavir/ritonavir, was examined in 80 treatment-naïve patients with a baseline HIV-1 viral load of more than 100 000 copies/ml. The time to virologic failure by 48 weeks was not different between the two groups. The percentage of patients with viral suppression was not significantly different with per protocol population. Tenofovir/emtricitabine showed better tolerability; more patients on abacavir/lamivudine changed regimen than those on tenofovir/emtricitabine. A randomized trial to elucidate the efficacy and safety of these two regimens is warranted.
- Published
- 2013
- Full Text
- View/download PDF
38. Blunted fetal growth by tenofovir in late pregnancy.
- Author
-
Kinai E, Hosokawa S, Gomibuchi H, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adenine adverse effects, Adult, Asian People, Female, HIV Seropositivity complications, Hepatitis B complications, Humans, Infant, Newborn, Pregnancy, Pregnancy Complications, Infectious virology, Tenofovir, Adenine analogs & derivatives, Anti-HIV Agents adverse effects, Bone Density drug effects, Fetal Growth Retardation chemically induced, HIV Seropositivity drug therapy, Hepatitis B drug therapy, Organophosphonates adverse effects, Pregnancy Complications, Infectious drug therapy
- Published
- 2012
- Full Text
- View/download PDF
39. Regulation of cell survival and death by pyridine nucleotides.
- Author
-
Oka S, Hsu CP, and Sadoshima J
- Subjects
- Adaptation, Biological physiology, Animals, Humans, Signal Transduction physiology, Cell Death physiology, Cell Survival physiology, NAD physiology, NADP physiology, Oxidative Stress physiology
- Abstract
Pyridine nucleotides (PNs), such as NAD(H) and NADP(H), mediate electron transfer in many catabolic and anabolic processes. In general, NAD(+) and NADP(+) receive electrons to become NADH and NADPH by coupling with catabolic processes. These electrons are utilized for biologically essential reactions such as ATP production, anabolism and cellular oxidation-reduction (redox) regulation. Thus, in addition to ATP, NADH and NADPH could be defined as high-energy intermediates and "molecular units of currency" in energy transfer. We discuss the significance of PNs as energy/electron transporters and signal transducers, in regulating cell death and/or survival processes. In the first part of this review, we describe the role of NADH and NADPH as electron donors for NADPH oxidases (Noxs), glutathione (GSH), and thioredoxin (Trx) systems in cellular redox regulation. Noxs produce superoxide/hydrogen peroxide yielding oxidative environment, whereas GSH and Trx systems protect against oxidative stress. We then describe the role of NAD(+) and NADH as signal transducers through NAD(+)-dependent enzymes such as PARP-1 and Sirt1. PARP-1 is activated by damaged DNA in order to repair the DNA, which attenuates energy production through NAD(+) consumption; Sirt1 is activated by an increased NAD(+)/NADH ratio to facilitate signal transduction for metabolic adaption as well as stress responses. We conclude that PNs serve as an important interface for distinct cellular responses, including stress response, energy metabolism, and cell survival/death.
- Published
- 2012
- Full Text
- View/download PDF
40. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
- Author
-
Nishijima T, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adult, Darunavir, Dideoxynucleosides administration & dosage, Drug Combinations, Female, HIV Protease Inhibitors administration & dosage, HIV-1, Humans, Lamivudine administration & dosage, Male, Pilot Projects, Retrospective Studies, Ritonavir administration & dosage, Sulfonamides administration & dosage, Treatment Outcome, Viral Load, Dideoxynucleosides therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Lamivudine therapeutic use, Ritonavir therapeutic use, Sulfonamides therapeutic use
- Abstract
The efficacy and safety of once-daily darunavir/ritonavir and fixed-dose abacavir/lamivudine was examined in 22 treatment-naïve patients with HIV-1 infection. Three patients discontinued antiretroviral therapy due to mild adverse events. Among 18 patients who continued therapy, 66.7% had viral load less than 50 copies/ml at week 48. Only two patients experienced virologic failure with the emergence of resistant virus. This pilot study demonstrated the viral efficacy and safety of darunavir/ritonavir and abacavir/lamivudine.
- Published
- 2012
- Full Text
- View/download PDF
41. Epstein-Barr virus associated colitis in an HIV-infected patient.
- Author
-
Hamada Y, Nagata N, Honda H, Asayama N, Teruya K, Igari T, Kikuchi Y, and Oka S
- Subjects
- AIDS-Related Opportunistic Infections complications, AIDS-Related Opportunistic Infections virology, Adult, Colitis, Ulcerative pathology, Diarrhea virology, Epstein-Barr Virus Infections complications, Gastrointestinal Hemorrhage virology, Humans, Immunohistochemistry, Male, AIDS-Related Opportunistic Infections pathology, Colitis, Ulcerative virology, Epstein-Barr Virus Infections pathology, Gastrointestinal Hemorrhage pathology
- Published
- 2012
- Full Text
- View/download PDF
42. Multiple cytokine-induced acute respiratory distress syndrome with a diffuse large B cell lymphoma, not otherwise specified.
- Author
-
Nakayama-Ichiyama S, Yokote T, Iwaki K, Hirata Y, Nishiwaki U, Masuda Y, Oka S, Akioka T, Miyoshi T, Tsuji M, and Hanafusa T
- Subjects
- Aged, Cytokines immunology, Humans, Lung Neoplasms immunology, Lung Neoplasms pathology, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Cytokines adverse effects, Lung Neoplasms complications, Lymphoma, Large B-Cell, Diffuse complications, Respiratory Distress Syndrome etiology
- Published
- 2011
- Full Text
- View/download PDF
43. Hypercalcaemia induced by tumour-derived parathyroid hormone-related protein and multiple cytokines in diffuse large B cell lymphoma, not otherwise specified.
- Author
-
Nakayama-Ichiyama S, Yokote T, Iwaki K, Hiraoka N, Hirata Y, Oka S, Akioka T, Miyoshi T, Takayama A, Nishiwaki U, Masuda Y, Tsuji M, and Hanafusa T
- Subjects
- Fatal Outcome, Humans, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse metabolism, Male, Middle Aged, Cytokines adverse effects, Hypercalcemia etiology, Lymphoma, Large B-Cell, Diffuse complications, Parathyroid Hormone-Related Protein adverse effects
- Published
- 2011
- Full Text
- View/download PDF
44. Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
- Author
-
Nishijima T, Tsukada K, Nagata N, Watanabe K, Teruya K, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Adult, Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Drug Therapy, Combination, Emtricitabine, Esophageal Diseases complications, HIV Infections complications, HIV Protease Inhibitors therapeutic use, Humans, Lopinavir, Male, Organophosphonates therapeutic use, Pyrimidinones therapeutic use, RNA, Viral blood, Ritonavir therapeutic use, Syndrome, Tenofovir, Ulcer complications, Antiviral Agents therapeutic use, Esophageal Diseases drug therapy, HIV Infections drug therapy, HIV-1, Ulcer drug therapy
- Published
- 2011
- Full Text
- View/download PDF
45. Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center.
- Author
-
Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, and Koike K
- Subjects
- Adult, Blood Coagulation, CD4 Lymphocyte Count, Hepatitis C drug therapy, Humans, Immunosuppression Therapy, Male, Survival Rate, HIV Infections complications, Hemophilia A complications, Hepatitis C complications, Liver Transplantation mortality, Living Donors
- Abstract
Background: Although almost all human immunodeficiency virus (HIV)-infected Japanese hemophiliacs are coinfected with hepatitis C virus (HCV), the outcome of living donor liver transplantation (LDLT) in such patients in terms of survival rate, perioperative complications, and recovery of coagulation activity is poorly understood., Patients and Methods: Six HIV-positive hemophiliacs underwent LDLT for HCV-associated advanced cirrhosis. The mean CD4 T-cell count at transplantation was 376±227/μL., Results: The 1-, 3-, and 5-year survival rates were 66%, 66%, and 50%, respectively. Fatal perioperative bleeding related to hemophilia was not observed. Two patients died within 6 months after transplantation due to graft failure. HIV infection was well controlled in all patients who survived longer than 6 months. Two patients (genotype 2a and 2+3a) achieved a sustained viral response and both of them were alive at the end of follow-up period, whereas one patient (genotype 1a+1b) died of decompensated cirrhosis 4 years after transplantation due to recurrent HCV infection., Conclusions: HIV/HCV-coinfected hemophiliacs can safely undergo LDLT. Hemophilia was clinically cured after successful transplantation. A good outcome can be expected as long as postoperative hepatitis C is controlled with interferon/ribavirin combination therapy.
- Published
- 2011
- Full Text
- View/download PDF
46. Thioredoxin binding protein-2 mediates metabolic adaptation in response to lipopolysaccharide in vivo.
- Author
-
Oka S, Liu W, Yoshihara E, Ahsan MK, Ramos DA, Son A, Okuyama H, Zhang L, Masutani H, Nakamura H, and Yodoi J
- Subjects
- Adaptation, Physiological, Animals, Blood Chemical Analysis, Blotting, Western, Carrier Proteins genetics, Cytokines metabolism, Disease Models, Animal, Endotoxemia metabolism, Endotoxemia physiopathology, Fatty Acids metabolism, Glucose metabolism, Immunohistochemistry, Injections, Intraperitoneal, Kaplan-Meier Estimate, Mice, Mice, Inbred C57BL, Mice, Knockout, Random Allocation, Reverse Transcriptase Polymerase Chain Reaction, Thioredoxins genetics, Carrier Proteins metabolism, Endotoxemia drug therapy, Endotoxemia mortality, Lipopolysaccharides pharmacology, Thioredoxins metabolism
- Abstract
Objectives: Endotoxin triggers a reorganization of the energy metabolic pathway, including the promotion of fatty acid utilization to adapt to a high energy demand during endotoxemia. However, the factors responsible for the metabolic adaptation and characteristic pathologies resulting from defective utilization fatty acids during endotoxin response have not been fully clarified. The thioredoxin binding protein-2 (TBP-2) knockout (TBP-2) mouse is an animal model of fatty acid oxidation disorder. The aim of this study was to determine whether and how TBP-2 is involved in metabolic regulation in a lipopolysaccharide (LPS)-induced endotoxemia model in mice., Design: Prospective animal trial., Setting: Research laboratory., Subjects: TBP-2 and wild control mice., Intervention: TBP-2 and wild control mice were intraperitoneally injected with LPS. Mortality, serum levels of markers of hepatorenal injuries, cytokines, insulin, glucose and lipid derivatives, and the hepatic signaling pathway regulating gluconeogenesis were investigated., Measurements and Main Results: Following the administration of LPS, TBP-2 mice showed a predisposition for death without any significant elevation of inflammatory cytokines, compared to the wild mice. LPS-challenged TBP-2 mice showed fat deposition in the liver and kidney, organ injuries, glycogen depletion, and elevation of serum lipid derivatives such as free fatty acids, triglyceride and cholesterol. Hyperinsulinemia and hypoglycemia were observed in TBP-2 mice after LPS injection. Death due to the LPS administration was prevented by supplementation of glucose. Phosphorylation of Akt and FoxO1, an inhibitory pathway of gluconeogenesis in the liver of LPS-challenged TBP-2 mice was demonstrated, suggesting the enhancement of insulin signaling., Conclusions: TBP-2 is involved in metabolic control during LPS-induced endotoxemia. After the LPS challenge, TBP-2 mice showed several characteristic aspects, such as hepatorenal injuries, and dysregulation of the lipid and glucose metabolisms. Furthermore, hypoglycemia promoted by hyperinsulinemia may be a critical risk factor for mortality in circumstances in which fatty acid utilization is impaired during endotoxemia.
- Published
- 2010
- Full Text
- View/download PDF
47. Silent information regulator 1 protects the heart from ischemia/reperfusion.
- Author
-
Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, Shao D, Takagi H, Oka S, and Sadoshima J
- Subjects
- Animals, Antioxidants metabolism, Apoptosis physiology, Cell Nucleus metabolism, Down-Regulation physiology, Forkhead Box Protein O1, Forkhead Transcription Factors genetics, Forkhead Transcription Factors metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Myocardial Reperfusion Injury pathology, Myocardium enzymology, Myocardium pathology, Superoxide Dismutase metabolism, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury physiopathology, Oxidative Stress physiology, Sirtuin 1 genetics, Sirtuin 1 metabolism
- Abstract
Background: Silent information regulator 1 (Sirt1), a class III histone deacetylase, retards aging and protects the heart from oxidative stress. We here examined whether Sirt1 is protective against myocardial ischemia/reperfusion (I/R)., Methods and Results: Protein and mRNA expression of Sirt1 is significantly reduced by I/R. Cardiac-specific Sirt1(-/-) mice exhibited a significant increase (44±5% versus 15±5%; P=0.01) in the size of myocardial infarction/area at risk. In transgenic mice with cardiac-specific overexpression of Sirt1, both myocardial infarction/area at risk (15±4% versus 36±8%; P=0.004) and terminal deoxynucleotidyl transferase dUTP nick end labeling-positive nuclei (4±3% versus 10±1%; P<0.003) were significantly reduced compared with nontransgenic mice. In Langendorff-perfused hearts, the functional recovery during reperfusion was significantly greater in transgenic mice with cardiac-specific overexpression of Sirt1 than in nontransgenic mice. Sirt1 positively regulates expression of prosurvival molecules, including manganese superoxide dismutase, thioredoxin-1, and Bcl-xL, whereas it negatively regulates the proapoptotic molecules Bax and cleaved caspase-3. The level of oxidative stress after I/R, as evaluated by anti-8-hydroxydeoxyguanosine staining, was negatively regulated by Sirt1. Sirt1 stimulates the transcriptional activity of FoxO1, which in turn plays an essential role in mediating Sirt1-induced upregulation of manganese superoxide dismutase and suppression of oxidative stress in cardiac myocytes. Sirt1 plays an important role in mediating I/R-induced increases in the nuclear localization of FoxO1 in vivo., Conclusions: These results suggest that Sirt1 protects the heart from I/R injury through upregulation of antioxidants and downregulation of proapoptotic molecules through activation of FoxO and decreases in oxidative stress.
- Published
- 2010
- Full Text
- View/download PDF
48. Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance.
- Author
-
Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Takiguchi M, and Oka S
- Subjects
- Drug Resistance, Viral immunology, HIV Infections drug therapy, HIV-1 drug effects, HLA-B Antigens genetics, Humans, Immune Evasion immunology, Immunodominant Epitopes, Molecular Sequence Data, Viral Load, Drug Resistance, Viral genetics, HIV Infections immunology, HIV-1 genetics, Immune Evasion genetics, Mutation immunology, Reverse Transcriptase Inhibitors therapeutic use, T-Lymphocytes, Cytotoxic immunology
- Abstract
Objective: The objective of this study is to determine the impact of human leukocyte antigen (HLA)-B*51-restricted cytotoxic T-lymphocyte (CTL) pressure on the development of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance., Design: The prevalence of HIV-1 harboring an escape mutation, I135X, in a major epitope of HLA-B*51-restricted CTL located in reverse transcriptase is increasing worldwide. We analyzed the effects of escape mutations on the emerging mutation patterns of NNRTI resistance., Methods: Monoclonal HIV-1 sequences harboring each of the escape mutations, including I135L (HIV-1I135L), I135V (HIV-1I135V), I135T (HIV-1I135T), and I135R (HIV-1I135R) in reverse transcriptase, and a wild-type monoclonal HIV-1 (HIV-1WT) were cultured in the presence of increasing concentrations of efavirenz. Induced mutations during culture passages of the culture were analyzed., Results: E138K emerged during the cultural passages of HIV-1I135V, HIV-1I135T, and HIV-1I135R, but not during the passages of HIV-1WT. The combination of I135T, the most frequent escape mutation, and E138K (HIV-1I135T/E138K) conferred significant resistance to efavirenz, nevirapine, and etravirine. The HIV-1I135L/E138K and HIV-1I135R/E138K were significantly resistant to nevirapine and etravirine, respectively, though each solo of escape mutations and E138K did not confer significant resistance to NNRTI. Computational analysis indicated that I135T and E138K cooperatively extend the gap between the binding site of reverse transcriptase and NNRTI., Conclusion: HLA-B*51-restricted CTL can induce novel mutation patterns of NNRTI resistance by selecting escape mutations. The spread of CTL escape variants may alter the mutation patterns of drug resistance.
- Published
- 2010
- Full Text
- View/download PDF
49. Raltegravir-associated perihepatitis and peritonitis: a single case report.
- Author
-
Tsukada K, Teruya K, Tasato D, Gatanaga H, Kikuchi Y, and Oka S
- Subjects
- HIV Infections complications, Hemophilia A complications, Hepatitis diagnostic imaging, Humans, Middle Aged, Peritonitis diagnostic imaging, Radiography, Raltegravir Potassium, HIV Infections drug therapy, Hemophilia A drug therapy, Hepatitis etiology, Peritonitis chemically induced, Pyrrolidinones adverse effects
- Published
- 2010
- Full Text
- View/download PDF
50. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
- Author
-
Hsu CP, Oka S, Shao D, Hariharan N, and Sadoshima J
- Subjects
- Adenosine Triphosphate metabolism, Animals, Animals, Newborn, Autophagy, Caspase 3 metabolism, Cells, Cultured, Cytochromes c, Cytokines genetics, Disease Models, Animal, Energy Metabolism, Mice, Mice, Transgenic, Myocardial Ischemia enzymology, Myocardial Ischemia pathology, Myocytes, Cardiac pathology, Nicotinamide Phosphoribosyltransferase genetics, RNA Interference, RNA, Messenger metabolism, Rats, Rats, Wistar, Reperfusion Injury enzymology, Reperfusion Injury pathology, bcl-X Protein metabolism, Apoptosis, Cytokines metabolism, Myocytes, Cardiac enzymology, NAD metabolism, Nicotinamide Phosphoribosyltransferase metabolism
- Abstract
Rationale: NAD+ acts not only as a cofactor for cellular respiration but also as a substrate for NAD(+)-dependent enzymes, such as Sirt1. The cellular NAD+ synthesis is regulated by both the de novo and the salvage pathways. Nicotinamide phosphoribosyltransferase (Nampt) is a rate-limiting enzyme in the salvage pathway., Objective: Here we investigated the role of Nampt in mediating NAD+ synthesis in cardiac myocytes and the function of Nampt in the heart in vivo., Methods and Results: Expression of Nampt in the heart was significantly decreased by ischemia, ischemia/reperfusion and pressure overload. Upregulation of Nampt significantly increased NAD+ and ATP concentrations, whereas downregulation of Nampt significantly decreased them. Downregulation of Nampt increased caspase 3 cleavage, cytochrome c release, and TUNEL-positive cells, which were inhibited in the presence of Bcl-xL, but did not increase hairpin 2-positive cells, suggesting that endogenous Nampt negatively regulates apoptosis but not necrosis. Downregulation of Nampt also impaired autophagic flux, suggesting that endogenous Nampt positively regulates autophagy. Cardiac-specific overexpression of Nampt in transgenic mice increased NAD+ content in the heart, prevented downregulation of Nampt, and reduced the size of myocardial infarction and apoptosis in response to prolonged ischemia and ischemia/reperfusion., Conclusions: Nampt critically regulates NAD+ and ATP contents, thereby playing an essential role in mediating cell survival by inhibiting apoptosis and stimulating autophagic flux in cardiac myocytes. Preventing downregulation of Nampt inhibits myocardial injury in response to myocardial ischemia and reperfusion. These results suggest that Nampt is an essential gatekeeper of energy status and survival in cardiac myocytes.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.